CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Capex Y/Y Annual
Celyad Oncology Sa  (CYAD)
Other Ticker:  
 
 

CYAD's Capital Expenditures Growth by Quarter and Year

Celyad Oncology Sa's Capital Expenditures results by quarter and year




CYAD Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 0.14 0.37 0.17 0.00
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   0.14 0.37 0.17 0.00



CYAD Capital Expenditures fourth quarter 2022 Y/Y Growth Comment
Celyad Oncology Sa reported drop in Capital Expenditures in the fourth quarter 2022 by -62.77% to $ 0.14 millions, from the same quarter in 2021.
The fall in the fourth quarter 2022 Celyad Oncology Sa's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures rise of 28.91%.

Looking into fourth quarter 2022 results within Major Pharmaceutical Preparations industry 226 other companies have achieved higher Capital Expenditures growth. While Celyad Oncology Sa' s Capital Expenditures meltdown of -62.77% ranks overall at the positon no. 3067 in the fourth quarter 2022.


CYAD Capital Expenditures ( Y/Y Growth %) 2022
 2021 2020 2019
IV Quarter December -62.77 % 117.65 % - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   -62.77 % 117.65 % - -

Financial Statements
Celyad Oncology Sa's fourth quarter 2022 Capital Expenditures $ 0.14 millions CYAD's Income Statement
Celyad Oncology Sa's fourth quarter 2021 Capital Expenditures $ 0.37 millions Quarterly CYAD's Income Statement
New: More CYAD's historic Capital Expenditures Growth >>


CYAD Capital Expenditures (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   -62.77 % 117.65 % - -


Suppliers by CYAD Divisions >> Back to CYAD Growth rate Comparisons >>


Capital Expenditures fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #227
Healthcare Sector #538
Overall #3067

Capital Expenditures Y/Y Growth Statistics
High Average Low
120.67 % 28.91 % -62.84 %
(Dec 31 2021)   (Dec 31 2022)
Capital Expenditures fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #227
Healthcare Sector #538
Overall #3067
Capital Expenditures Y/Y Growth Statistics
High Average Low
120.67 % 28.91 % -62.84 %
(Dec 31 2021)   (Dec 31 2022)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Celyad Oncology Sa's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYAD's IV. Quarter Q/Q Capital Expenditures Comment


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYAD's IV. Quarter Q/Q Capital Expenditures Comment


Celyad Oncology Sa's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2022)		 12 Months Ending
0		 12 Months Ending
0		 12 Months Ending
0		 12 Months Ending
(Dec 31 2021)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.37
Y / Y Capital Expenditures Growth (TTM) - - - - 120.67 %
Year on Year Capital Expenditures Growth Overall Ranking # 337 # 0 # 0 # 0 # 340
Seqeuential Capital Expenditures Change (TTM) - - - - -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # # # # #

New: More CYAD's historic Capital Expenditures Growth >>



Cumulative Capital Expenditures growth Comment
In the Dec 31 2022 period, Celyad Oncology Sa's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

In the Healthcare sector 62 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 337.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 63
Overall # 337

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
120.67 %
120.67 %
120.67 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Capital Expenditures growth Comment
In the Dec 31 2022 period, Celyad Oncology Sa's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

In the Healthcare sector 62 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 337.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 63
Overall # 337

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
120.67 %
120.67 %
120.67 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
CYAD's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for CYAD's Competitors
Capital Expenditures Growth for Celyad Oncology Sa's Suppliers
Capital Expenditures Growth for CYAD's Customers

You may also want to know
CYAD's Annual Growth Rates CYAD's Profitability Ratios CYAD's Asset Turnover Ratio CYAD's Dividend Growth
CYAD's Roe CYAD's Valuation Ratios CYAD's Financial Strength Ratios CYAD's Dividend Payout Ratio
CYAD's Roa CYAD's Inventory Turnover Ratio CYAD's Growth Rates CYAD's Dividend Comparisons



Companies with similar Capital Expenditures meltdown for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2022
Encompass Health Corporation-0.10%$ -0.099 millions
Abbott Laboratories-0.65%$ -0.651 millions
Qualigen Therapeutics Inc -0.69%$ -0.687 millions
Rxsight Inc -0.82%$ -0.822 millions
Cryoport inc -0.94%$ -0.936 millions
Acadia Healthcare Company Inc -0.94%$ -0.941 millions
Alnylam Pharmaceuticals Inc -1.15%$ -1.147 millions
Achilles Therapeutics Plc-1.60%$ -1.598 millions
Regeneron Pharmaceuticals Inc -1.74%$ -1.743 millions
Warby Parker Inc -1.93%$ -1.932 millions
Gsk Plc-2.47%$ -2.474 millions
Emergent Biosolutions Inc -2.78%$ -2.784 millions
Ligand Pharmaceuticals Incorporated-2.92%$ -2.916 millions
Community Health Systems Inc -2.96%$ -2.963 millions
Vir Biotechnology Inc -3.60%$ -3.604 millions
1life Healthcare Inc -4.08%$ -4.082 millions
Henry Schein Inc-4.32%$ -4.319 millions
Pharvaris N v -4.41%$ -4.411 millions
Tenet Healthcare Corp-4.61%$ -4.605 millions
Merck and Co Inc -4.88%$ -4.884 millions
Edwards Lifesciences Corporation-5.01%$ -5.011 millions
Veru Inc -5.51%$ -5.507 millions
Opko Health Inc -5.85%$ -5.854 millions
Cano Health Inc -5.97%$ -5.973 millions
Axogen inc -6.31%$ -6.311 millions
Si bone inc -6.48%$ -6.479 millions
Qilian International Holding Group Limited-6.71%$ -6.710 millions
Treace Medical Concepts Inc -7.05%$ -7.055 millions
Iqvia Holdings Inc -7.07%$ -7.065 millions
Teva Pharmaceutical Industries Limited-7.19%$ -7.190 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com